Joseph Dedvukaj

All Posts

• Arena's Marketing Partner Eisai Projects Sales To 4 Million Obese Patients By 2016

  By Joseph Dedvukaj - May 17, 2013 | Tickers: ARNA, VVUS

  Arena (Nasdaq: ARNA) and Eisai have an accurate picture of the potential value of Belviq by doing early stage market research. Eisai is in the top 25 largest pharmaceutical companies in the world. Eisai is a successful leading pharmaceutical company by both demonstrating an understanding of the importance of marketing and cleverly integrating it with the science. In accordance with the marketing agreement between the two companies, Eisai did the more »

• The DEA Confirmed Physicians Can Combine Belviq-Phentermine

  By Joseph Dedvukaj - May 9, 2013 | Tickers: ARNA

  Arena's (ARNA) new FDA approved obesity drug will be debuting on June 7, 2013, just in time for summer weather across the United States when most people use outdoor activities to try to lose weight and live healthier. Scientists at the DEA recently announced that they welcomed into the world of drug compounds the newest molecule Belviq (Lorcaserin) as a schedule IV controlled substance. The molecule was developed and more »

• Arena's Short Interest Continues To Be Held At Bay While Fundamentals Play Out

  By Joseph Dedvukaj - December 17, 2012 | Tickers: ARNA

  Arena (NASDAQ: ARNA) short interest has grown to a peak of 61,748,793 shares on Nov 15 2012. Followed by the most recent decline to 56,263,870. Some smart shorts exited their positions. A short squeeze can be deliberately induced by a hedge fund or institution at any moment. We savvy investors closely monitor the daily available to short box to determine whether or not shorts are having more »

• The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

  By Joseph Dedvukaj - December 13, 2012 | Tickers: ARNA, VVUS

  Arena's weight management drug Belviq has been approved by the FDA for marketing in the United States. A few weeks ago, I wrote an article detailing Arena's path to profitability. I remain optimistic about Arena's prospects for global success in the obesity market. One big reason is, as of the writing of this article, we have learned Arena (NASDAQ: ARNA) is getting closer to approval for its more »

• What Investors Should Know And Do To Make Sure The Short Interest In Arena's Stock Is Playing By The Rules.

  By Joseph Dedvukaj - November 26, 2012 | Tickers: ARNA, BAC, BCS, SCHW, C, CS, DB, ETFC, GS, HBC, JPM, MFG, NES.DL, PJC, RBS, BA, TST, UBS, WFC

  1. Arena (NASDAQ: ARNA) short-sellers using illegal short and distort-

  As of November 15, 2012, Arena short interest is 61,748,793 shares. This is the highest it has ever been. How much of the short interest is illegal naked shorting? We believe its substantial. It is no secret Arena investors know illegal naked short selling and stock manipulation are being used to manipulate Arena's stock to some extent more »

• Arena Pharmaceuticals - The Obesity Blockbuster Drug Company and More

  By Joseph Dedvukaj - September 18, 2012 | Tickers: ARNA, AZN, MRK, PFE

  Retail investors were right and Wall Street was wrong about the approval of Arena Pharmaceuticals, Inc's (NASDAQ: ARNA) lead drug candidate Belviq (Lorcaserin). Here are the four coming catalysts for Arena:

  1. The Obesity epidemic gives Arena's Belviq blockbuster drug status.

  2. The growing obesity market is enormous and Belviq has a broad label.

  3. Physicians control the demand for Belviq not the consumer.

  4. ARNA is a more »